Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval

 
• By Sten Stovall

Celltrion's version of Roche’s MabThera (rituximab), Truxima, has become the first biosimilar anticancer to win marketing authorization in Europe.

European Union

More from New Products

More from Scrip